| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 05/13/2009 | EP2056806A2 Use of certain chemical compounds for the inhibition of the peptidyl-prolyl cis/trans isomerase activity of cyclophilins |
| 05/13/2009 | EP2056805A1 Use of 2, 5-dihydroxybenzene derivatives for the treatment of tissue reactive diseases |
| 05/13/2009 | EP2056804A1 Use of 2,5-dihydroxybenzene derivatives for the treatment of ocular diseases |
| 05/13/2009 | EP2056803A2 Thiol-based agents for reducing toxicities associated with medical procedures employing radiographic contrast agents |
| 05/13/2009 | EP2056802A2 Anti-diabetes composition containing chicoric acid and/or one of the metabolites thereof |
| 05/13/2009 | EP2056801A1 Ruthenium ii compounds |
| 05/13/2009 | EP2056800A2 Therapy procedure for drug delivery for trigeminal pain |
| 05/13/2009 | EP2056799A2 Compositions and methods for treating or preventing glaucoma or progression thereof |
| 05/13/2009 | EP2056797A2 Controlled release system and method for manufacturing the same |
| 05/13/2009 | EP2056796A2 Lyophilized preparation |
| 05/13/2009 | EP2056794A2 Multistage delivery of active agents |
| 05/13/2009 | EP2056792A2 Drug delivery systems comprising solid solutions of weakly basic drugs |
| 05/13/2009 | EP2056790A2 Galenic formulations of aliskiren |
| 05/13/2009 | EP2056675A2 Methods of treating oral mucositis |
| 05/13/2009 | EP2056673A2 Combination treatment for metabolic disorders |
| 05/13/2009 | EP1981505A4 Preparation of 7-alkenyl-3 quinolinecarbonitriles via a palladium mediated coupling reaction |
| 05/13/2009 | EP1965768B1 Fexofenadine suspension formulation |
| 05/13/2009 | EP1926723B1 Azabicyclo (3,1,0) hexan derivatives useful as modulators of dopamine d3 rceptors |
| 05/13/2009 | EP1912957A4 Ep4 receptor agonist, compositions and methods thereof |
| 05/13/2009 | EP1893208B1 Pharmaceutical composition comprising a 1-(3-chlorophenyl)-3-alkylpiperazine for treating apetite disorder |
| 05/13/2009 | EP1856041B1 Crystallisation and purification of glycopyrronium bromide |
| 05/13/2009 | EP1828197B1 NOVEL SUBSTITUTED THIOPHENEPYRIMIDINONE DERIVATIVES AS INHIBITORS OF 17ß-HYDROXYSTEROID DEHYDROGENASE |
| 05/13/2009 | EP1788876B1 Method for manufacturing imidazole compounds and salts and pseudopolymorphs thereof |
| 05/13/2009 | EP1758565B1 Method of identifying GLP-1 secretagogues |
| 05/13/2009 | EP1753712B1 Amino-propanol derivatives |
| 05/13/2009 | EP1753434B1 Enhanced bimatoprost ophthalmic solution |
| 05/13/2009 | EP1721610B1 Composition containing benzamidine derivative and method for stabilizing benzamidine derivative |
| 05/13/2009 | EP1711485B1 Amino-benzimidazoles derivatives as inhibitors of respiratory syncytial virus replication |
| 05/13/2009 | EP1694323A4 Methods of treating a disorder |
| 05/13/2009 | EP1687301B1 Thiaepothilone for treating cancerous diseases |
| 05/13/2009 | EP1678135B1 Process for the preparation of n-amino substituted heterocyclic compounds |
| 05/13/2009 | EP1655028B1 Use of cyclic bioisosteres of purine system derivatives for the treatment of diseases caused by disorders of nitrergic and dopaminergic systems |
| 05/13/2009 | EP1648471A4 Methods for the treatment of male and female sexual dysfunction |
| 05/13/2009 | EP1587795B1 N- (1-benzyl-2-oxo-2- (1-piperazinyl) ethyl) -1-piperidincarboxamid-derivatives and related compounds use as cgrp-antagonists for treating a headache |
| 05/13/2009 | EP1565429B1 Diaryl ureido derivatives and their medical use |
| 05/13/2009 | EP1562927B1 Thio-analogues of paclitaxel and intermediates thereof |
| 05/13/2009 | EP1556013B1 Deferasirox dispersible tablets |
| 05/13/2009 | EP1549624B1 Inhibitors of fatty acid amide hydrolase |
| 05/13/2009 | EP1535616B1 Remedy for integration dysfunction syndrome |
| 05/13/2009 | EP1515972B1 Amide substituted xanthine derivatives with gluconeogenesis modulating activity |
| 05/13/2009 | EP1490490B1 Antisense iap nucleobase oligomers and uses thereof |
| 05/13/2009 | EP1473298B1 Supermolecular carboplatinum derivatives, their preparation and pharmaceutical composition containing them as active ingredient and applications of the compositions |
| 05/13/2009 | EP1469866B1 Cycloglycans suitable to inhibit mammalian infection |
| 05/13/2009 | EP1466174B1 Mutations in the bcr-abl tyrosine kinase associated with resistance to sti-571 |
| 05/13/2009 | EP1429770B1 New formulations and use thereof |
| 05/13/2009 | EP1397356B1 Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (pai-1) |
| 05/13/2009 | EP1385525B1 Targeted oxidative therapeutic formulation |
| 05/13/2009 | EP1377570B1 Substituted 2-carba-3,5-dicyano-4-aryl-6-aminopyridines and the use of the same as selective ligands of the adenosine receptor |
| 05/13/2009 | EP1356812B1 Medicines for treatment and prevention of neurogenic pain |
| 05/13/2009 | EP1355646B1 Muscarinic receptor agonists |
| 05/13/2009 | EP1327440B1 Oral preparations with favorable disintegration characteristics |
| 05/13/2009 | EP1320540B1 Peptidomimetic protease inhibitors |
| 05/13/2009 | EP1317536B1 Tnf receptor-like molecules and uses thereof |
| 05/13/2009 | EP1305026B1 Barbituric acid analogs as therapeutic agents |
| 05/13/2009 | EP1299388B1 Variolin derivatives as anti-cancer agents |
| 05/13/2009 | EP1299104B1 Tamper-resistant oral opioid agonist formulations |
| 05/13/2009 | EP1261340B1 Compositions and methods for the treatment of parkinson's disease |
| 05/13/2009 | EP1259474B1 Calcium dicarboxylate ethers, methods of making same |
| 05/13/2009 | EP1220617B1 Fish feed with increased nucleotide content |
| 05/13/2009 | EP1062209B1 Metabolically inert anti-inflammatory and anti-tumor antifolates |
| 05/13/2009 | EP0934311B1 New heterocyclylmethyl-substituted pyrazol derivates |
| 05/13/2009 | CN101432287A Pyrrolopyrimidine derivatives used as HSP90 inhibitors |
| 05/13/2009 | CN101432286A Novel 1,4-diaza-bicyclo[3.2.2]nonyl oxadiazolyl derivatives and their medical use |
| 05/13/2009 | CN101432285A Pyrazolo-tetrahydro pyridine derivatives as orexin receptor antagonists |
| 05/13/2009 | CN101432284A Dihydropyrazolopyrimidinone derivative |
| 05/13/2009 | CN101432283A N- (2-thiazolyl) -amide derivatives as GSK-3 inhibitors |
| 05/13/2009 | CN101432282A N- (2-thiazolyl) -amide derivatives as GSK-3 inhibitors |
| 05/13/2009 | CN101432281A 6-o-substituted benzoxazole and benzothiazole compounds and methods of inhibiting CSF-1R signaling |
| 05/13/2009 | CN101432280A Neurogenesis inducer or neuropathy therapeutic agent comprising alkyl ether derivative or salt thereof |
| 05/13/2009 | CN101432279A N-oxides of pyridylmethylpiperazine and -piperidine derivatives |
| 05/13/2009 | CN101432278A Diketo-piperazine and piperidine derivatives as antiviral agents |
| 05/13/2009 | CN101432277A Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 |
| 05/13/2009 | CN101432276A Quinoline derivatives |
| 05/13/2009 | CN101432275A Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 |
| 05/13/2009 | CN101432274A Sulfonyl-3-heterocyclylindazole derivatives as 5-hydroxytryptamine-6 ligands |
| 05/13/2009 | CN101432269A 1-sulfonylindazolylamine and -amide derivatives as 5-hydroxytryptamine-6 ligands |
| 05/13/2009 | CN101432268A Derivatives of 4-(2-amino-1-hydroxiethyl)phenol as agonists of the ss2 adrenergic receptor |
| 05/13/2009 | CN101432265A Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 |
| 05/13/2009 | CN101432264A Salts with CRTH2 antagonist activity |
| 05/13/2009 | CN101432263A Substituted pyrrolidinones as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 |
| 05/13/2009 | CN101432262A Cyclohexyl substituted pyrrolidinones as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 |
| 05/13/2009 | CN101432261A N-benzoyl-and N-benzylpyrrolidin-3-ylamines as histamine-3 antagonists |
| 05/13/2009 | CN101432256A Method for stabilization of reduced coenzyme Q10 |
| 05/13/2009 | CN101432020A Methods and materials for the inhibition of transplant rejection |
| 05/13/2009 | CN101432012A Pharmaceutical combination for the treatment and or chemosensibilization of refractory tumors to anticancer drugs |
| 05/13/2009 | CN101432009A Preventative treatment and remission of allergic diseases |
| 05/13/2009 | CN101432005A Polymer-based anti-cancer agents |
| 05/13/2009 | CN101432004A Combination therapy for controlled carbohydrate digestion |
| 05/13/2009 | CN101432003A Noncardiotoxic pharmaceutical compounds |
| 05/13/2009 | CN101432002A Method and composition for treating chronic obstructive pulmonary disease |
| 05/13/2009 | CN101432001A Small molecules that replace or agonize P53 function |
| 05/13/2009 | CN101432000A Prophylactic or therapeutic agent for allergic ophthalmic disease or allergic nasal disease comprising tricyclic triazolobenzoazepine derivative |
| 05/13/2009 | CN101431999A Use of VX-702 for treating rheumatoid arthritis |
| 05/13/2009 | CN101431998A Pharmaceutical compositions comprising CBx cannabinoid receptor modulators and potassium channel modulators |
| 05/13/2009 | CN101431997A Melatonin and immunostimulating substance-based compositions |
| 05/13/2009 | CN101431996A Inhibitors of protein prenyltransferases |
| 05/13/2009 | CN101431995A Stable vitamin C compositions |
| 05/13/2009 | CN101431994A Use of CBx cannabinoid receptor modulators as potassium channel modulators |
| 05/13/2009 | CN101431993A Use of DHA and ARA in the preparation of a composition for regulating gene expression |
| 05/13/2009 | CN101431992A Novel low dose pharmaceutical compositions comprising nimesulide, preparation and use thereof |